Nitrosative stress drives heart failure with preserved ejection fraction
Author
dc.contributor.author
Schiattarella, Gabriele G.
Author
dc.contributor.author
Altamirano, Francisco
Author
dc.contributor.author
Tong, Dan
Author
dc.contributor.author
French, Kristin M.
Author
dc.contributor.author
Villalobos, Elisa
Author
dc.contributor.author
Kim, Soo Young
Author
dc.contributor.author
Luo, Xiang
Author
dc.contributor.author
Jiang, Nan
Author
dc.contributor.author
May, Herman I.
Author
dc.contributor.author
Wang, Zhao V.
Author
dc.contributor.author
Hill, Theodore M.
Author
dc.contributor.author
Mammen, Pradeep
Author
dc.contributor.author
Huang, Jian
Author
dc.contributor.author
Lee, Dong I.
Author
dc.contributor.author
Hahn, Virginia
Author
dc.contributor.author
Sharma, Kavita
Author
dc.contributor.author
Kass, David A.
Author
dc.contributor.author
Lavandero González, Sergio
Author
dc.contributor.author
Gillette, Thomas G.
Author
dc.contributor.author
Hill, Joseph A.
Admission date
dc.date.accessioned
2019-10-22T03:15:00Z
Available date
dc.date.available
2019-10-22T03:15:00Z
Publication date
dc.date.issued
2019
Cita de ítem
dc.identifier.citation
Nature . 2019 April ; 568(7752): 351–356
Identifier
dc.identifier.issn
14764687
Identifier
dc.identifier.issn
00280836
Identifier
dc.identifier.other
10.1038/s41586-019-1100-z
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/172051
Abstract
dc.description.abstract
Heart failure with preserved ejection fraction (HFpEF) is a common syndrome with high morbidity and mortality for which there are no evidence-based therapies. Here we report that concomitant metabolic and hypertensive stress in mice—elicited by a combination of high-fat diet and inhibition of constitutive nitric oxide synthase using N ω -nitro-l-arginine methyl ester (l-NAME)—recapitulates the numerous systemic and cardiovascular features of HFpEF in humans. Expression of one of the unfolded protein response effectors, the spliced form of X-box-binding protein 1 (XBP1s), was reduced in the myocardium of our rodent model and in humans with HFpEF. Mechanistically, the decrease in XBP1s resulted from increased activity of inducible nitric oxide synthase (iNOS) and S-nitrosylation of the endonuclease inositol-requiring protein 1α (IRE1α), culminating in defective XBP1 splicing. Pharmacological or genetic suppression of iNOS, or cardiomyocyte-restricted overexpression of XBP1s, each ameliorated the HFpEF phenotype. We report that iNOS-driven dysregulation of the IRE1α–XBP1 pathway is a crucial mechanism of cardiomyocyte dysfunction in HFpEF.